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The chemokine receptor CCR7 is widely implicated in breast cancer pathobiology. 
Although recent reports correlated high CCR7 levels with more advanced tumor grade and 
poor prognosis, limited in vivo data is available regarding its specific function in mammary 
gland neoplasia and the underlying mechanisms involved. To address these questions we 
generated a MMTV-PyMT Ccr7
-/-
 bigenic mouse breast cancer model which revealed that 
CCR7 ablation results in a considerable delay in tumor onset as well as significantly reduced 
tumor burden. Importantly, CCR7 was found to exert its function by regulating mammary 
cancer stem-like cells in both murine and human tumors. In vivo experiments showed that 
loss of CCR7 activity either through deletion or pharmacological antagonism significantly 
decreased functional pools of stem-like cells in mouse primary mammary tumors, providing a 
mechanistic explanation for the tumor-promoting role of this chemokine receptor. These data 
characterize the oncogenic properties of CCR7 in mammary epithelial neoplasia and point to 
a new route for therapeutic intervention to target evasive cancer stem cells.  
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Despite concerted efforts and significant advances, breast cancer-related mortality is 
still a leading cause of death in women worldwide (1). Clearly novel therapies are urgently 
needed. The “cancer stem cell” theory specifies that a small subset of cells in a heterogeneous 
tumor (termed “cancer stem cells” (CSCs)) possess stem cell-like properties of self-renewal 
and differentiation. CSCs are suggested to sustain and propagate tumors, and are inherently 
therapy-resistant (for the latest reviews see (2) and (3)).   
CSCs may originate from adult stem cells, but can also arise from more committed 
lineage progenitor cells if they acquire stem cell-like features due to genetic or epigenetic 
changes (4). Multiple intrinsic and extrinsic factors are reported to play a role in CSC 
maintenance, regulation and support of stem-like characteristics. Most prominent are the 
Notch (5), Hedgehog (6), Wnt (7) and TGFβ (8) signaling systems. Several cytokines and 
chemokines have been recently suggested as maintaining and promoting the CSC phenotype 
in a number of solid malignancies, including mammary tumors (reviewed in (9)), however, 
definitive in vivo data has been sparse.  
Chemokine receptors and their cognate chemokine ligands have become widely 
accepted as important mediators of cancer growth and progression in many human 
neoplasms, being involved in tissue transformation, invasion, angiogenesis, and resistance to 
chemotherapy (10). Amongst these, the chemokine receptor CCR7 has been implicated in 
metastatic spread of multiple malignancies (11). In breast carcinogenesis it has been 
attributed a number of potential functions, including promotion of cell motility, migration and 
adhesion, regulation of matrix metalloproteinases leading to basement membrane degradation 
(12), and cell survival through inhibition of anoikis (13). Data obtained using cell lines has 
implicated CCR7 in breast cancer spread to the lymph nodes (14), and in human breast cancer 
its role was inferred from retrospective studies on archived tumor tissues (15). High 
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expression levels of CCR7 were also correlated with higher grade and occurrence of 
secondary tumors, and poor prognosis (16, 17).  
Whilst all these studies point to a role for CCR7 in malignancy, a direct function for 
CCR7 in cancer has not yet been established. Furthermore, its role in breast cancer in 
particular is unclear. We show here the development of a novel bigenic mouse model 
combining deletion of CCR7 with the polyoma middle-T transgene, which is under control of 
the mouse mammary tumor virus promoter (MMTV-PyMT), to study tumor development in 
vivo. Using this model we show that CCR7 deletion has a striking preventative effect on 
PyMT-driven mammary tumors, supporting the notion that CCR7 plays a major determining 
role in breast oncogenesis. Moreover, our data reveal that the tumor-promoting effect of 
CCR7 is mediated through stem-like cells in both primary mouse and human breast tumors. 
These results provide new insights into the role of CCR7 in breast cancer stem-like cells and 












CCR7 deletion arrests mammary tumourigenesis in the PyMT transgenic breast cancer 
mouse model 
The MMTV-PyMT transgenic breast cancer mouse model has been extensively used 
in recent years to study various aspects of mammary neoplasia. Expression of the PyMT 
protein promotes the rapid epithelial transformation of mammary cells, via the corruption of 
various pathways including those of Src, ras, and PI3 kinase. This model also results in 
spontaneous metastasis and has been found to closely mimic the development of human 
breast cancer (18-20). Representative images are shown in Supplementary Figure 1a, in 
which α-smooth muscle actin (α-SMA) is used to stain myoepithelial cells. 
To directly assess the role of CCR7 in the multistage process of mammary 
tumourigenesis in vivo, we generated bigenic MMTV-PyMT Ccr7
-/-
 knock-out mice (further 
referred to as CCR7 KO+) and traced the development of mammary tumors relative to 
MMTV-PyMT Ccr7
WT
 mice (further referred to as WT+).  
Deletion of CCR7 significantly delayed PyMT-driven primary mammary 
tumourigenesis (representative pictures Figure 1a). Tumor-free survival was significantly 
extended (Figure 1b) and total tumor burden was markedly reduced in CCR7 KO+ mice 
(Figure 1c) when compared to the WT+ animals. The lungs of WT+ and CCR7 KO+ females 
were also examined for metastatic lesions at the time of sacrifice. CCR7 KO+ mice 
developed significantly fewer and smaller metastases than WT+ mice (Figure 1d-f), although, 
the number of metastases varied largely between mice of the same genotype.  
As these experiments indicated a role for CCR7 in mammary gland function, we next 
examined normal, pre-cancerous and cancer-bearing mouse mammary glands for CCR7 
expression and signaling. CCR7 was shown to be expressed on all mouse mammary epithelial 
cells tested regardless of the tumor stage (Supplementary Figure 1b), and the removal of 
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CCR7 did not affect the expression levels of its ligands CCL19 and CCL21 within the mouse 
fat pad (Supplementary Figure 2a). CCR7 was also found to be functional in PyMT-driven 
mammary tumors, as tumor cells mobilized intracellular calcium, a hallmark of chemokine 
receptor activity, in response to stimulation with CCL21 (Supplementary Figure 2b). These 
data showed that CCR7 was expressed and was functional within normal and transformed 
mammary epithelium.  
Interestingly, despite the large impact of CCR7 on overall mammary tumourigenesis, 
initial PyMT-driven hyperplastic growth in 8 or 11 week old WT+ and CCR7 KO+ mice was 
not affected (Supplementary Figure 3a), with similar tissue architecture in glands from both 
genotypes (Supplementary Figure 3b). This indicated that the CCR7 KO+ mammary glands 
underwent the initial oncogenic transformation leading to epithelial proliferation, but further 
tumourigenic transition was largely blocked by CCR7 deletion. 
CCR7 promotes tumourigenesis by amplifying breast cancer stem-like cells  
In order to investigate the underlying mechanisms responsible for the tumourigenic 
effects seen, we examined the roles of CCR7 in mammary gland development and on stem-
like cells. We found that in non-PyMT wild-type (WT) pubertal mice, the epithelial tree was 





2a-b), indicating that ablation of CCR7 had a mild inhibitory effect on pubertal growth of the 
mammary gland epithelium. CCR7 was robustly expressed in normal mammary epithelium 
(Figure 2c), making this receptor also potentially relevant to normal mammary development. 
However, development of mammary epithelium in the CCR7 KO mice caught up with that of 
the WT mice by the age of 8 weeks, and at 12 weeks mammary glands from the two 
genotypes were indistinguishable (Figure 2d), demonstrating that CCR7 deletion mainly 
delays early mammary gland development. 
CCR7 promotes breast cancer via stem-like cells 
7 
 
Because normal development and breast cancer are believed to be linked by common 
regulatory mechanisms, we hypothesized that the observed promotion of PyMT-driven 
tumourigenesis and mammary development was due to CCR7 regulating stem/progenitor cell 









 cell surface marker profile (4), which was 
previously functionally characterized in the MMTV-PyMT model (21, 22). CCR7 was 
expressed in all cell lineages in both the normal and PyMT-expressing mammary glands 







normal and cancer mouse mammary stem cell-enriched 





 putative mammary stem cells (23) from both normal and breast 
tumor tissue (Figure 3b, Supplementary Figure 4c). 







in non-PyMT CCR7 KO mice relative to WT (Figure 3c left panel). In PyMT-expressing 
mice at the stage of early neoplasia, when no morphological differences were found in WT+ 
and CCR7 KO+ glands (Supplementary Figure 3) and the stem/progenitor cell populations 
may therefore best reflect the tumor-initiating cell content, the difference in the stem cell-
enriched population between WT+ and CCR7 KO+ mice was even more pronounced with the 
deletion of CCR7 leading to a 2-fold reduction in stem-like cells (Figure 3c right panel).  
Recently Pece et al have suggested a new and potentially more efficient set of 
markers, in which the Notch ligands
 
Delta-Like Ligand 1 (DLL1) and Delta and Notch-like 










) to delineate putative stem cells in human mammary tumors (24). We 
found that the stem-like cells from both human and mouse mammary glands defined by this 
profile also expressed high levels of CCR7 (Supplementary Figure 4d-e). Moreover, the Lin
-









 cell pools were significantly smaller in both normal and PyMT-
expressing CCR7 KO murine mammary glands (Supplementary Figure 5a-b) providing 
further support for the findings described above.  
It is generally accepted that non-adherent passaged mammosphere cultures are 
enriched in cells with stem-like characteristics, and secondary/tertiary mammosphere-
forming efficiency (MFE) is representative of cells’ potential to exhibit stem cell traits (25-
27). Stem-like activity, as measured by MFE, was then analyzed in the mammary epithelium 
in the presence or absence of CCR7. Primary and secondary sphere formation from normal 
(Figure 3d) or PyMT-expressing (Figure 3e) mammary cells was substantially reduced after 
CCR7 ablation and, importantly, stimulation of WT and WT+ cells with CCR7 ligands 
CCL19 and CCL21 significantly potentiated mammosphere growth (Figure 3d-e).  
This CCR7 stimulatory function was seen exclusively on mammosphere growth, as 
stimulation with CCL19 and CCL21 had no detectable effect on the proliferation of bulk 
mammary tumor cells in adherent cultures, a condition that supports a more differentiated 
phenotype (Supplementary Figure 5c). The addition of CCR7 ligands to sphere cultures 
derived from CCR7 KO+ mammary cells also had no effect on MFE (Supplementary Figure 
5d), demonstrating a CCR7 receptor-mediated mechanism. The specificity of CCR7 was 
further shown by testing a panel of ligands for other tumor-associated chemokine receptors 
CCR6 (16), CXCR3 (28) and CXCR5 (29). No effects were observed on MFE 
(Supplementary Figure 5e).  
In order to extend these findings to human breast cancer we next examined the 
activity of CCR7 in human primary tumor cells from resected breast cancer tissue. The 
addition of CCL19 and CCL21 resulted in an increase in primary and secondary MFE of 
human breast cancer cells by 2- to 3-fold (Figure 3f), consistent with results obtained in the 
mouse model. 
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To specifically link the deletion of CCR7 to depleted tumor-initiating cells, a limiting 
dilution transplantation approach was used (24) to estimate tumor-initiating cell frequency. 
Secondary mammosphere-derived cells from WT+ and CCR7 KO+ mice with early neoplasia 
were used in this assay to address the potential of cells in mammosphere cultures to exhibit 
stem cell traits of self-renewal and tumor initiation in vivo, in the context of CCR7-
dependency. Cells were injected into contralateral inguinal fat pads of non-PyMT WT 
recipients. Analysis of grafted fat pads after 6 weeks showed that WT+ sphere cells produced 
much more robust growth at all dilutions (Figure 4a and Supplementary Figure 6). Most 
importantly, the frequency of stem-like cells capable of tumor initiation within WT+ sphere 
culture (1/189) was over 3-fold higher than in CCR7 KO+ (1/913) (Figure 4b), providing 
strong evidence for the critical role of CCR7 in the regulation and maintenance of stem-like 
cells and tumor-initiating cells in the mammary gland.  
CCR7 is required for the propagation of mammary tumors 
In order to obtain in vivo evidence for the role of CCR7 in tumor propagation, we 
took advantage of the PyMT mouse model which allows tumor formation upon 
transplantation (20). Expression of the PyMT oncogene results in multifocal tumors and 
hence can generate diverse CSC pools due to various underlying mutations in different foci 
within the same gland at the late stages of tumourigenesis. Therefore we reasoned that if 
taken at the early stage of pre-neoplastic tumor development, the population of CSCs should 
be more homogeneous. Consequently, small 1mm
3 
fragments of pre-neoplastic mammary 
tissue from 8 week old PyMT transgenic WT+ and CCR7 KO+ mice were simultaneously 
transplanted into contralateral inguinal mammary fat pads of non-PyMT WT recipients. 
Representative histological sections from both WT+ and CCR7 KO+ 8 week old mice, 
corresponding to donor tissue, are shown in Figure 5a, confirming that the glands used for 
transplantation were at the equivalent stage of tumourigenesis. 
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Analysis of tumourigenic outgrowth from transplanted tissue showed that the deletion 
of CCR7 almost completely blocked secondary tumor development. Only 1 out of 6 
transplants from the CCR7 KO+ donors was able to give rise to a neoplastic lesion whereas 5 
out of 6 fragments from the WT+ donors produced secondary outgrowths in WT recipients 
(Figure 5b-c), demonstrating a key role of CCR7 in tumor propagation.  
Pharmacological antagonism of CCR7 in vivo depletes the stem-like cell population and 
inhibits mammary tumourigenesis 
A CCR7 antagonist, CCL19(8-83) (30), was employed to explore the potential of 
targeting CCR7 for CSC-directed therapeutic intervention. Initially, the ability of CCL19(8-83) 
to block the stimulatory activity of CCR7 ligands on mammosphere-forming capacity was 
tested ex vivo and found to specifically abrogate the effect of CCL21 (Figure 6a) and CCL19 
(data not shown) on mammosphere growth providing a rationale for in vivo studies. 
 The effect of CCR7 blockade by CCL19(8-83) on tumor initiation was then examined 
in the context of the PyMT transgenic mouse model. CCL19(8-83) was injected for 8 
consecutive weeks into inguinal mammary glands of animals from the age of 4 weeks old. 
Glands were then excised and examined for the extent of tumourigenesis and stem-like cell 
content and function. Macroscopic analysis demonstrated that CCL19(8-83)-injected glands 
had smaller lesions than their control counterparts (representative image Figure 6b). The total 
weight of fat pads was not statistically different; however, the cellularity (total cell count and 
cells per mg of tissue) was significantly reduced by the antagonist (Figure 6c, Supplementary 
Figure 7a-b).  
















Supplementary Figure 7c) and the function of stem and early progenitor cells (Figure 6d right 
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panel), without affecting the level of CCR7 receptor expression (Supplementary Figure 7d). 
Both FVB and C57B/l6 (not shown) PyMT transgenic mice were tested, with similar results. 
To determine if treatment with CCL19(8-83) has an inhibitory effect on established 
and/or advanced later stage tumors, 1mm
3 
size fragments of MMTV-PyMT WT+ tumors 
from 16 week old mice, corresponding to the invasive ductal carcinoma stage of human 
breast cancer (Supplementary Figure 1a), were transplanted into inguinal glands of WT 
recipients followed by 8 weekly injections of CCL19(8-83) or vehicle control (Figure 6e left 
panel). Whilst no significant differences were seen between CCL19(8-83)- or vehicle-treated 
tumors in size or cellularity (Supplementary Figure 7e) as was observed in primary tumors, 















Supplementary Figure 7f) marker sets, 
as well as mammosphere growth (Figure 6e right panel), were significantly reduced in 
antagonist-treated glands, demonstrating that the CCR7 axis can be blocked in vivo to target 
stem-like cells in mammary tumors.  




 The contribution of CSCs to tumor initiation is a major issue in tumor biology yet one 
of the least understood processes (3). We show here that ablating CCR7 using a bigenic 
MMTV-PyMT Ccr7
-/- 
model significantly depleted the breast cancer stem cell-enriched pool. 











showed that the underlying mechanism involves a decrease in the ability of stem-like cells 
and early progenitor cells to self-renew and initiate neoplasia. Significantly, exogenously 
targeting CCR7 with a peptide antagonist led to a decrease in tumourigenesis. 
CCR7 has been extensively studied for its role in adaptive immunity and secondary 
lymphoid organogenesis, and CCR7-null mice display disrupted architecture of the thymus 
and lymph node, as well as a reduced ability to mount a primary immune response (31). The 
role of CCR7 in mediating anti-tumor immunity is also slowly emerging (32). In this context, 
the fact that abrogation of CCR7 severely affected mammary tumourigenesis provides 
definitive evidence of CCR7 as a pro-tumourigenic driver. Furthermore, numerous 
transplantation approaches used in this study underscore an immune system-independent role 
of this chemokine receptor in maintaining stem-like cell pools in breast cancer.  
Interestingly, hyperplastic outgrowth, widely believed to be a precursor of mammary 
tumors (20), was found in 100% of WT and CCR7 KO PyMT-carrying glands examined. 
However, the majority of CCR7 KO+ glands were unable to sustain this initial proliferative 
burst of tumor cells and progress to the next stage in tumor development. Therefore, the delay 
in mammary tumourigenesis appears to be due to CCR7 maintaining specialized hierarchical 
sub-populations of cancer stem and progenitor-like cells that are thought to be crucial for 
tumor initiation and advanced tumourigenesis (2).  
The fact that both CCL19 and CCL21 stimulated mammosphere growth from both 
human and mouse tumor cells strongly suggests that CCR7 plays a global role in sustaining 
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properties of stemness in mammary epithelium. The specificity of CCR7 in this process was 
validated through testing a panel of chemokine receptor ligands, where only CCL19 and 
CCL21 showed an ability to significantly increase mammosphere-forming efficiency.  
Stimulation of CXCR4, the chemokine receptor that is consistently found to be 
upregulated together with CCR7 in a number of cancers (17), did potentiate sphere formation 
but to a lesser extent (Supplementary Figure 5e). Recently, Clarke and colleagues 
demonstrated that stimulation of CXCR4 also increased MFE preferentially in malignant 
breast cancer cell lines compared to normal breast cell lines (26). It is interesting to speculate 
that as CCR7 is less important for homeostasis than CXCR4, as has been inferred from 
animal models (33), CCR7 may represent a more attractive target for future CSC-targeting 
therapies.  
As stimulation of CCR7 had no effect on proliferation of the bulk population of cells 
when seeded into adherent culture, compared to a highly significant effect in non-adherent 
culture, it is likely that CCR7 predominantly mediates specific cellular properties of 
stemness. Moreover, we have previously reported that CCR7 activation on breast cancer cells 
inhibits anoikis (13), a characteristic of breast and other CSCs (25, 34). Therefore, it is 
plausible that CCR7 supports CSC survival without attachment to the extracellular matrix, a 
hypothesis which may form the basis for future studies.  
 CCR7 appeared to play a quantitative rather than a qualitative role in normal 
mammary stem cells compared to cancer stem cells. Upon deletion of CCR7 we saw a mild 
effect on the normal mammary gland. In contrast, a major effect was seen in mammary 
tumourigenesis. Interestingly, whilst the morphological effect on normal mammary gland 
development was not extensive, CCR7 deletion discreetly affected normal mammary gland 
stem-like cells. Therefore, it is plausible that CCR7 has a role in regulating the properties of 
stemness within the mammary epithelial cell population, an effect which appears more 
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prominent during cancer progression. As highlighted in a recent study by Cheresh and 
colleagues (35), dysregulation of normal stem cells may contribute to breast cancer 
progression and stemness, and CCR7 may emerge as a novel mediator of this transition.  
 Translation of our findings from the mouse model to human disease is of particular 
significance considering that there is currently no clear consensus on the markers that define 
functional mammary stem cells in both mice and humans. Thus we show here that CCR7 not 
only plays a role in mouse mammary tissue, but is also expressed, is functional, and is highly 
responsive in the stem-like populations within human breast cancer tissue. Intriguingly, 
circulating tumor cells, an indicator of metastatic spread and poor outcome in breast and 
other cancers, have been recently equated to CSCs (36). In the last decade numerous studies 
also suggested a role for CCR7 in malignant dissemination of mammary tumors to distant 
sites (13, 15, 17). Taken together, these results suggest a novel causative link between CCR7 
activity on stem-like populations and metastatic breast cancer.  
In order to seek proof-of-principle on the utility of pharmacologically targeting CCR7 
we tested the receptor antagonist CCL19(8-83) (30). We found that pharmacological inhibition 
of CCR7 through direct mammary fat pad injection of CCL19(8-83) afforded a significant 
reduction in early stage primary mammary tumourigenesis. Since the relative contribution of 
the malignant lesions to the weight of the whole mammary fat pad was very small at this 
early stage the reduction in total weight between antagonist and vehicle treated glands was 
not statistically significant. However the cellularity, a characteristic that directly reflects the 
extent of epithelial malignant outgrowth and is used in clinical pathology to evaluate the 
response to chemotherapy in breast cancer, was strongly impacted by treatment with the 
CCR7 antagonist.  
More importantly, directly targeting CCR7 using the antagonist significantly depleted 
the stem-like cell pools in both early and late stage mammary neoplasia as was shown using 
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the transplantation approach. These findings strongly suggest that the CCR7 receptor axis is a 
potential point of intervention in stem cell-targeting therapies and provide a rationale for the 
use of antagonists of this pathway as adjuvants to conventional cytotoxic drugs unable to 
eliminate quiescent cancer stem cells (2).  
In conclusion, the characterization of CCR7 in primary breast tumourigenesis in vitro 
and in vivo, and in mouse and human tissue, strongly suggests a role for this molecule in 
breast cancer development and progression. These insights raise the possibility of 
pharmacologically targeting CCR7 for the development of new therapies in breast cancer.  
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MATERIALS and METHODS 
Mice 
Mice were maintained in pathogen-free conditions in the University of Adelaide’s 
Laboratory Animal Services facility. Ccr7
-/- 
mice were purchased from Jackson Laboratory. 
FVB MMTV-PyMT (+) mice were backcrossed for 14 generations to C57Bl/6 background, 
and C57Bl/6 background was confirmed by microsatellite analysis. PyMT-carrying males 
were then crossed with Ccr7
-/-
 females, and the offspring were interbred to produce MMTV-
PyMT Ccr7
WT
 and MMTV-PyMT Ccr7
-/-
 mice. The University of Adelaide institutional 
animal ethics committee approved all experimentation. For the assessment of CCR7 
expression and CCL19(8-83) function both C57Bl/6 and FVB backgrounds were tested to 
eliminate any strain bias. For experiments involving knock-out mice, only C57Bl/6 mice 
were tested. Nomenclature used for genotypes is as follows: Ccr7
WT





= WT+, MMTV-PyMT Ccr7
-/- 
= CCR7 KO+.  
Human Mammary Tissue 
Ethical approval was granted by the Royal Adelaide Hospital Ethics Committee and 
all patients gave written, informed consent prior to surgery. Pathology reports for tumors 
used are available upon request. Normal breast tissue samples were obtained from the Queen 
Elizabeth Hospital, Adelaide.  
Whole Mount Staining 
Mammary glands were fixed in Carnoy’s and were stained overnight in Carmine 
Alum before dehydration and mounting. Image “stitching” and analysis was performed using 
Image J. 
Histology 
Lungs of MMTV-PyMT WT+ or CCR7 KO+ mice were perfused and dissected, then 
embedded and frozen in OCT and serially sectioned at 9μm. Formalin-fixed paraffin-
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embedded (FFPE) mammary glands/tumors were sectioned at 5μm. All slides were stained 
using haemotoxylin and eosin (H&E), dehydrated and mounted. Slides were scanned using 
the NanoZoomer Digital Pathology (NDP) System (Hamamatsu Photonics) and lung sections 
were manually quantitated using the NDP Virtual Slide Viewer software for number of 
metastases and area at the largest point.   
Immunofluorescent Microscopy 
Antigen retrieval of FFPE mouse mammary sections was performed by boiling slides 
in 0.1 M sodium citrate buffer (pH 6.0). Slides were stained with rabbit anti-CCR7 
(Epitomics) overnight at 4°C, and primary antibody was detected with Alexa Fluor 488-
conjugated goat anti-rabbit (Invitrogen) for 30 minutes. Slides were counterstained with 
DAPI, mounted, and analyzed using the Leica TCS SP5 Confocal Microscope System. 
Processing Mouse Mammary Tissue to Single Cell Suspension 
Mouse mammary glands/tumors were dissected, with removal of the lymph node if 
possible. Tissue was manually dissociated and then digested in 10% 
collagenase/hyaluronidase (Stem Cell Technologies) for 3-4 hours with gentle tilting. Single 
cells were extracted as previously described (37) and filtered through a 70μm nylon mesh. In 
order to remove contaminating infiltrating cells of hematopoietic origin, Biotin Binder 
Dynabeads (Invitrogen) in combination with a biotinylated anti-mouse lineage antibody panel 
(BioLegend), were used as suggested by the manufacturer.  
Processing Human Mammary Tissue to Single Cell Suspension 
Surgical specimens were minced and digested in 10% collagenase/hyaluronidase 
(Stem Cell Technologies) in DMEM supplemented with 20mM HEPES, penicillin-
streptomycin, and 0.25μg/ml fungazone. Organoids were then extensively washed with 
DMEM and red blood cells were lysed by isotonic lysis buffer (150mM NH4Cl in 17mM 
Tris-HCl, pH 7.2). Single cell suspensions were obtained by digesting organoids with 0.25% 
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trypsin for 10 minutes at room temperature, with subsequent filtration through a 70μm nylon 
mesh. 
Flow Cytometry  
Cells were fixed in 4% paraformaldehyde and immunostained for 45 minutes on ice in 
PBS/0.5%BSA. Antibodies used were: Alexa Fluor 647-conjugated anti-mouse CCR7, PE-
conjugated anti-mouse/anti-human CD24, FITC/PECy5-conjugated anti-human CD49f, 
FITC-conjugated anti-human CD44 (all from BD), FITC-conjugated anti-mouse CD29, PE-
conjugated anti-mouse/anti-human DLL1 (all from BioLegend), and biotinylated anti-
mouse/anti-human DNER (R&D). Samples containing biotinylated antibodies were 
resuspended in PerCP/Cy5.5 or Alexa Fluor 488-conjugated streptavidin (1/1000 dilution) in 
PBS/0.5% BSA for 30 minutes on ice. Fluorescence-minus-one (FMO) samples or 
conjugated isotypes were used as negative controls. Flow cytometry was carried out using 
FACSCanto equipment (BD). Data analysis was performed using FlowJo software (Tree Star 
Inc.).  
Mammosphere Assay 
Cells were seeded in mammosphere medium (1:1 mixture of DMEM and Ham’s F12 
medium (Gibco) supplemented with 1xB27 (Invitrogen), 20ng/ml EGF, 20ng/ml bFGF, 
4μg/ml heparin (Sigma-Aldrich), penicillin-streptomycin, and 0.25μg/ml fungazone) at 
4x10
4
cells/ml to an ultra-low attachment tray (Corning). Where indicated, CCL21, CCL19 
and CCL19(8-83) were added at concentrations of 10ng/ml, 200ng/ml and 100ng/ml 
respectively. Media was replenished every second day. After 7-10 days, mammospheres were 
counted and passaged.  
Limiting Dilution Assay 
Mammosphere colonies derived from 8 week old pre-neoplastic MMTV-PyMT WT+ 
and CCR7 KO+ mice were dissociated using trypsin and triturated through a 19G needle. 
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Following filtration, cells were injected in 20% Matrigel (BD):80% DMEM into the fourth 
inguinal mammary glands of anaesthetized WT recipient mice (8 weeks old) at limiting 
dilutions as previously described (24). Mice were sacrificed after 6 weeks and glands whole-
mounted. TIC-frequency and statistical calculations were performed using L-Calc software 
(Stem Cell Technologies).  
Tissue Transplants 
Mammary gland fragments of 1mm
3
 size from donor MMTV-PyMT mice were 
transplanted into contralateral sides of anaesthetized congenic non-PyMT WT recipient mice 
(8 weeks old) within the fourth inguinal mammary glands. Mice were monitored for adverse 
reactions to surgery and subsequent tumor growth.  
In vivo Treatment with CCR7 Antagonist 
Mice were injected under anesthetic into an inguinal mammary fat pad, with 1μg 
CCL19(8-83) truncated ligand in 50μl saline vehicle, as indicated. As a control, mice were 
injected in the contralateral inguinal mammary fat pad with vehicle alone as previously 
reported (38, 39).  
Statistical Analysis 
Unless otherwise indicated, analyses were carried out using GraphPad Prism and data 
is shown as mean ± SEM. Significant statistical difference was estimated using student’s t-
tests, or chi-square tests for distribution analysis. Tumor-free survival curves were graphed 
using the Kaplan-Meier method and distributions were compared by the log-rank statistic 
(Mantel-Cox test). All measurements were done in triplicate. P-values were used to denote 
statistical significance. Levels of significance were *p≤0.05, **p≤0.01, and ***p≤0.001. 
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Figure 1: CCR7 deletion arrests mammary tumourigenesis in the PyMT transgenic 
breast cancer mouse model 
(a-c) CCR7 ablation delays tumor onset and reduces tumor burden in the MMTV-PyMT-
driven mouse model of breast cancer. (a) Representative images of MMTV-PyMT Ccr7
WT
 
(WT+) and MMTV-PyMT Ccr7
-/-
 (CCR7 KO+) mice at 22 weeks old, showing grossly 
visible tumors (demarcated by red arrows and dotted lines). (b) Kaplan-Meier analysis of 
tumor-free survival for WT+ (n=18) and CCR7 KO+ (n=17) mice. (c) Number of tumors in 
WT+ and CCR7 KO+ mice at the time of sacrifice. (d-f) CCR7 KO+ mice developed less 
lung metastases than their WT+ counterparts. (d) Total cumulative area of lung metastatic 
lesions in WT+ (n=8) and CCR7 KO+ (n=8) mice. (e) Distribution data of lung metastases in 
WT+ and CCR7 KO+
 
mice. (f) Representative images of H&E stained lung sections from 
WT+ (left) and CCR7 KO+ (right) mice with metastatic lesions (black arrowheads). Red 
arrowhead indicates inset magnified image.  
Figure 2: The effect of CCR7 on normal mammary development 
(a-b) Development of the mammary ductal tree was evaluated in Ccr7
WT
 (WT) and Ccr7
-/-
 
(CCR7 KO) C57Bl/6 mice at 6 weeks of age. (a) Representative whole mount images of 
mammary glands, with apparent reduction in the size of ductal trees in CCR7 KO (right, n=6) 
compared to WT (left, n=7). LN= lymph node. (b) Quantitation of the length of the main 
epithelial duct (left), total number of mammary epithelial terminal structures (center), and 
branch points within mammary epithelium determined by quantifying branch points per mm 
along three individual ducts (right). (c) CCR7 expression (magenta) in normal mouse 
mammary terminal end buds of pubertal mice. Nuclei are counterstained with DAPI (gray). 
(d) Representative whole mount images of mammary glands taken from adult WT (left, n=6) 
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and CCR7 KO (right, n=6) mice at 12 weeks of age with no apparent differences in the size 
and architecture of the mammary tree.  
Figure 3: CCR7 activity amplifies stem-like cells in both mouse and human mammary 
glands 
(a-c) Normal mammary glands and mammary tumors were analyzed by flow cytometry for 
stem-like cell content. (a) Proportion of cells positive for CCR7 in Lin
-
 stem cell-enriched 
populations in normal mouse mammary epithelium (left) and PyMT-expressing glands 




. Shaded histograms= 
fluorescence-minus-one negative gates. (b) Proportion of cells positive for CCR7 in putative 
stem-like cell populations in normal human mammary epithelium (left) and breast cancer 




. (c) CCR7 deletion decreases 
the proportion of mouse Lin
- 
stem cell-enriched populations in normal (left) and PyMT-
expressing (right) mammary glands as indicated. (d-f) The effect of CCR7 deletion/activation 
on primary and secondary mammosphere formation was assessed. Shown are mammosphere-
forming efficiencies of cells derived from normal mouse mammary glands (d), PyMT-
expressing mouse mammary glands (e), and human patient-derived breast tumors (f). WT 
mouse cells and primary human cells were stimulated with CCL21 and CCL19 as indicated. 
(a-f) Mouse data are representative of at least 3 independent experiments, n=6-10 mice per 
group. Human results are representative of 2 normal and 4 independent tumor samples.  
Figure 4: CCR7 increases in vivo tumor-initiating capacity of sphere cells  
(a) Representative images of intact and respective whole-mounted contralateral mammary 
glands engrafted with 2500 WT+ or CCR7 KO+ sphere-derived cells. Black arrowheads 
indicate areas of outgrowth from engrafted cells. LN= lymph node. (b) Results of limiting 
dilution assay indicating frequency of tumor-initiating cells (TIC) in WT+ and CCR7 KO+ 
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sphere cultures. Fractions indicate the number of fat pads with lesion(s) per total number of 
recipient fat pads.  
Figure 5: CCR7 is required for the propagation of mammary tumors 
(a) Representative H&E stained sections of pre-neoplastic mice at the WT+ and CCR7 KO+ 
donor age of 8 weeks. Bottom: Magnified images of boxed area. (b) Representative whole-
mount images of WT
 
recipient glands after transplantation of pre-neoplastic mammary tissue 
from WT+ (top) and CCR7 KO+ (bottom) donor mice at 8 weeks of age. Black arrowheads 
indicate areas of outgrowth from donor tissue. Fractions indicate the number of fat pads with 
lesion(s) per total number of recipient fat pads. LN= lymph node. (c) Cumulative area of 
transplant outgrowth in recipient mammary glands. n=6 mice per group.  
Figure 6: Pharmacological antagonism of CCR7 in vivo depletes the stem-like cell 
population and inhibits mammary tumourigenesis 
(a) MFE of Lin
-
 mammary cells from WT+ mice (n=9), untreated or treated with CCL21 
and/or the CCR7 antagonist CCL19(8-83). (b-d) Treatment of mice with CCL19(8-83) reduces 
tumourigenesis in MMTV-PyMT WT+ mice. (b) Representative image of intact mammary 
glands treated with vehicle or CCL19(8-83) as indicated. (c) Cellularity of contralateral vehicle- 






 cells (left) and MFE 
(right) of cells from vehicle- or CCL19(8-83)- treated glands. (e) Treatment of mice with 
CCL19(8-83) reduces the stem cell-enriched population in a transplant model. Experimental 






 cells (center) and MFE (right) of cells from 
transplanted tumors with or without CCL19(8-83) treatment. (b-e) Data are representative of 2 












Supplementary Experimental Procedures 
Immunohistochemistry (IHC) 
Immunohistochemical analysis was performed using standard procedures. Briefly, 
antigen retrieval of FFPE mouse mammary sections was carried out by boiling slides in 0.1M 
sodium citrate buffer (pH 6.0) under pressure. Slides were immersed in 3% hydrogen 
peroxide in PBS for 20 minutes with gentle agitation to inhibit endogenous peroxidase 
activity and blocked for 30 minutes in 10% normal serum in PBS to prevent non-specific 
antibody binding. Slides were then incubated overnight at 4°C with mouse anti-α-smooth 
muscle actin (α-SMA, Dako). Specific antibody binding was detected using the EnVision 
Dual Link System (Vector Labs) followed by incubation with diaminobenzidine (DAB) 
substrate (Dako). Sections were counterstained with haemotoxylin, dehydrated and mounted. 
Calcium (Ca
+
) Signaling Analysis 
Intracellular calcium mobilization assay was performed on cells isolated from tumors 
dissected from C57Bl/6 MMTV-PyMT mice at 20 weeks of age as described (1). Ligands 
added were CCL21 (100ng/ml) and lysophosphatidic acid (LPA) (50ng/ml). 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Wells were coated in CCL21 and CCL19 capture antibody (R&D) and receptors 
blocked using PBS/3%BSA for 1 hour at 37°C. After determining WT and CCR7 KO 
mammary gland weight, fat pad samples were homogenized in PBS buffer (10% glycerol, 1x 
protease inhibitor) and aliquotted to coated wells for 90 minutes at 37°C. Detection antibody 




Isolated lineage-negative mouse mammary cells were plated in adherent culture 
(DMEM:F12/10% FCS, supplemented with 20ng/ml EGF, 5μg/ml insulin, 0.5μg/ml 
hydrocortisone, penicillin-streptomycin, and 0.25μg/ml fungazone) in 96-well plates and the 
following day were serum-starved for 4 hours. The cell proliferation assay was carried out 24 
hours later using the XTT Cell Proliferation Kit (ATCC) according to manufacturer’s 
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Supplementary Figure 1 (Related to Figure 1)  
(a) Serial sections of mouse mammary tissue from normal mice and at different tumourigenic 
stages stained with haemotoxylin and eosin (H&E) and for α-smooth muscle actin (α-SMA) 
as indicated. (b) Mammary cells were gated to exclude debris, dead cells and doublets (top) 
and proportions of CCR7-positive cells in mammary epithelial cell preparations from 
corresponding stages in (a) were analyzed by flow cytometry(bottom). Shaded histograms= 
fluorescence-minus-one negative gate. wo= weeks old. 
Supplementary Figure 2 (Related to Figure 1)  
(a) Expression of CCR7 ligands (CCL21 and CCL19) in WT and CCR7 KO mammary fat 
pads with excised inguinal lymph nodes was assessed by ELISA. n=6 glands per genotype. 
(b) Calcium mobilization analysis of PyMT-expressing WT+ mouse mammary cells in 
response to lysophosphatidic acid (LPA) (positive control) and the CCR7 ligand, CCL21. 
Arrowheads indicate a point of stimulus addition. 
Supplementary Figure 3  
Ablation of CCR7 has no effect on early mammary tumourigenesis in MMTV-PyMT mice. 
(a) Top: Representative images of inguinal mammary glands of WT+ (left) and CCR7 KO+ 
(right) mice harvested at 8 and 11 weeks of age as indicated. Arrowheads indicate areas of 
epithelial hyperplasia. LN= lymph node. Bottom: Quantitation of area of hyperplasia in WT+ 
and CCR7 KO+ at 8 weeks old. n=6 glands per genotype. (b) Serial sections of mouse 
mammary tissue from WT+ and CCR7 KO+ mice at 8 weeks old stained with haemotoxylin 
and eosin (H&E) and for α-smooth muscle actin (α-SMA) as indicated. 
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Supplementary Figure 4 (Related to Figure 3)  
All cells were pre-gated to exclude debris, dead cells and doublets. (a-b) Flow cytometry 









cells and stromal cells) and proportion of CCR7 positive 
cells within these populations, in normal mice (a) and from MMTV-PyMT mice (b). (c) Flow 









) in human mammary epithelium, and proportion 
of CCR7 positive cells within these populations as indicated. (d-e) Flow cytometry gating 







 surface marker expression, together with representative 
plots demonstrating proportion of CCR7 positive cells within these populations. “FMO” and 
shaded histograms= fluorescence minus one negative gates. 
Supplementary Figure 5 (Related to Figure 3)  
(a-b) CCR7 deletion decreases proportion of the stem cell-enriched population in normal (a) 








. Data are representative of at least three independent experiments, n=6 
mice per genotype. (c) CCR7 stimulation does not have any effect on proliferation of WT+ 
mammary cells in adherent culture. Shown are results of XTT proliferation assay with and 
without addition of CCR7 ligands. FCS was used as a positive control. (d) The stimulatory 
effect of CCL19 and CCL21 on MFE of MMTV-PyMT cells is dependent on CCR7. The 
primary MFE of CCR7 KO+
 
(n=4 mice) mouse mammary cells was not affected by the 
addition of these chemokines. (e) Effect of stimulation of primary WT+ (n=6 mice) 




Supplementary Figure 6 (Related to Figure 4)  
Representative images of WT recipient glands engrafted with WT+ or CCR7 KO+ 
mammosphere-derived cells as indicated. Shown are contralateral glands in which both WT+ 
and CCR7 KO+ cells produced outgrowths (black arrowheads), to demonstrate differences in 
size between lesions. At the lowest dilution, only WT+ cells produced any outgrowth. LN= 
lymph node.  
Supplementary Figure 7 (Related to Figure 6)   
 (a) Total mammary epithelial cell count in MMTV-PyMT mice following injection with 
vehicle or CCL19(8-83) antagonist for 8 weeks in contralateral inguinal mammary fat pads. (b) 
Weight of mammary glands. (c) Comparison of stem cell-enriched population in MMTV-








. (d) Treatment 
of mammary glands with vehicle control (left) or CCL19(8-83) (right) does not alter CCR7 






 population. Shaded histograms = fluorescence 
minus one negative gates. (e) Treatment with CCL19(8-83) does not change cellularity of 
transplanted tumor tissue despite affecting the stem cell-like pool. (f) Comparison of the stem 
cell-enriched population in transplanted glands treated with CCL19(8-83) or vehicle, as 
delineated by alternative marker set Lin
-
CD49f
+
DLL1
+
DNER
+
.  







